The University of Angers

The University of Angers (UA) is a comprehensive public university with 1000 permanent faculties, 18 500 students. 20% of its doctoral students are in Biology and Health.
Local PhD training is achieved through strong research teams, totalling 240 staff belonging to the Research Institute in Cell Interactions and Therapeutic Applications and the Regional doctoral school in Biology and Health of Nantes and Angers. Nanomedicine is a flagship programme of the UA with an internationally recognised research team.The UA has hosted several conferences in nanomedicine, and possesses the necessary facilities, such as the University-Hospital Common Animal Experimentation Centre, to develop nanomedicine devices. It’s a founding member of the Regional Pole of Research and Higher Education (PRES) of the Pays de la Loire for whom research in health is a major priority.

The UA will be the coordinating institution of the NanoFar programme.
The 20 years experience of the International Office in managing European and international programmes, including Tempus and Leonardo, and the international activity of the School of  Pharmacy (numerous Erasmus and other exchanges, member of a Health and Biomedical research consortium) ensure its achievement and specific staff will be hired to in this way.

The International Office has a specific service for incoming students and the Central Research Division provides support for international programmes through the European Unit and the doctoral training centre. All of the EMJD partner institutions are already partners with Angers Health Science researchers. The UA will host kick-off meetings and doctoral training schools, as well as organisational meetings for administrators of the programme. It will take in charge the internal and external communication of the consortium.

Website: University of Angers


The consortium academic partners are at the forefront of developments in nanomedicine at the European level.

They are dedicated to offering the highest quality education through well recognized doctoral school and international programmes. The consortium brings experience in terms of management and organization.

  • The University of Nantes (UN) and the University of Angers (UA) and their Doctoral school in Biology and Health (Director Pr. C.Tellier, UN, Co-Director Pr. F. Boury, UA), innovates across all disciplines linked to nanomedicine design (Pr. J.P. Benoit) use of radiopharmaceuticals (Dr. J. Barbet, Director of Aronax) and their application in therapy (Pr. O. Couturier and Pr. P. Menei) and tissue engineering (Pr. P. Weiss) (in tight collaboration with hospitals where clinical trials on nanomedical devices have been conducted).

Click here to read the University of Angers presentation

Click here to read the University of Nantes presentation

  •  The Université catholique de Louvain (UCL) and the University of Liège (ULg) excel in Doctoral training through Thematic Doctoral School in pharmaceutical sciences (Director Pr. V. Préat) and material chemistry of National Fund of Scientific research. Belgium groups experience in research is complementary through drug delivery systems (Pr. V. Préat), polymer chemistry (Pr. C. Jérome), Cancer research (Pr. O.Feron) and medical imaging (Pr. A. Luxen, Pr. B.Gallez) or nuclear medicine (Pr. R. Huxtin).

Click here to see the Université catholique de Louvain presentation

Click here to see the University of Liège presentation

  •  The University of Nottingham (UNott) has a Doctoral Training Centre in Targeted Therapeutics with strong expertise in polymer conjugates based therapies (Pr. A. Cameron) and a world-leading role in tissue engineering and regenerative medicine (Pr. K.M. Shakesheff).

Click here to see the University of Nottingham presentation

  •  The University of Santiago de Compostela (USC) (International Excellency Campus Vida) has a leading pole in nanotechnologies applied to the design of Drug Delivery Systems (Pr.. M.J Alonso) with strong existing technology transfers towards the clinic (Pr.. R. Lopez) and industry.

Click here to see the University of Santiago de Compostela presentation

The NanoFar consortium forms the largest research community in nanomedicine in Europe. The research laboratories bring together more than 300 researchers in the concerned field.

NanoFar offers a training environment that will inspire students to tackle difficulties associated with the multiple levels of nanomedicine using new and multidisciplinary techniques with a clear translational perspective on bedside-to-bench and bench-to-bedside activities.
This is possible thanks to its associated partners.

Click here to acceed the presentation of NanoFar associated partners


The Supervisory Board
The supervisory board is composed of 12 full members:
  • 2 senior scientists from UA/UN, 2 from ULC/ULg, 2 from USC and 2 from UNott
  • the administrative coordinator
  • the NanoFar coordinator
  • 2 external members recognized for their expertise.
and 4 consultative members:
  • 2 representatives of the associated partners.
  • 2 PhD students
The Management Board
The Management Board consists of:
  • The NanoFar Coordinator
  • The administrative coordinator
  • 6 senior academic members managing the Committees
Committee 1 “Internal and external communication”
Committee 2 “Education and Training”
Committee 3 “Selection of the applicant students”
Committee 4 “Mobility”
Committee 5 “Follow-up of the students and professional insertion
Committee 6 “Career opportunities”

PhD degrees

The NanoFar Network education and research policy follows the guidelines of the Bologna Declaration in order to create a frontier-free science in Europe, the consolidation of excellence in research and teaching, and the establishment of a sustainable education system that allows the effective professional recognition of the degrees.
Students will be assessed jointly by  two universities and will be awarded a dual PhD diploma by the two institutions.

Erasmus Mundus

NanoFar project is among the 10 joint doctoral programmes selected in 2011 for funding by the European Commission under the Erasmus Mundus program.

See selected Action 1 – Erasmus Mundus Joint Doctorate projects until 2012

See selected projects from 2014

Erasmus Mundus 2009-2013 is a cooperation and mobility programme in the field of higher education for :
  – the enhancement of quality in European higher education;
  – the promotion of the European Union as a centre of excellence in learning around the world;
  – the promotion of intercultural understanding through coopera­tion with Third Countries as well as for the development of Third Countries in the field of higher education.

The European Commission is responsible for the running of the Erasmus Mundus Programme 2009-2013. It manages the budget and sets priorities, targets and criteria for the Programme. Furthermore, it guides and monitors the general implementation, follow-up and evaluation of the Programme at European level.

The Education, Audiovisual and Culture Executive Agency (EACEA) is responsible for the implementation of the Erasmus Mundus Programme. (Source : Executive Agency Education, Audiovisual & Culture) 


ec_erasmus_mundus_en-petit   Read more about Erasmus Mundus on


The training activities of NanoFar will allow the students to benefit fully from the complementarity leading-edge science specialisations of each partner :

– Design of nanomedicine devices,
– Applications of nanomedicine for imaging and radiotherapy,
– Interaction between biological systems and artificial nanostructures,
– Nanomedicine in therapy and regenerative medicine,
– Moving nanomedicine from the laboratory to the clinic.

These topics will be explored at every NanoFar summer school held annually in the partners’ countries and completed by top-level thematic courses at each university.

Multidisciplinary core skills acquired during the curriculum will enable the young scientists to master, throughout the programme, the translational and bench-to-bedside approaches relevant to nanomedicine.

Transferable skills, including academic language and writing, career management, communication, research environment and context, are a central component of this PhD.
NanoFar accomodates 10 to 15 new PhD students per year (from EU and third countries). Fair selection and employment opportunities are a priority for the NanoFar consortium.